30,949 Shares in Cassava Sciences, Inc. (NASDAQ:SAVA) Purchased by Apollon Wealth Management LLC

Apollon Wealth Management LLC bought a new stake in Cassava Sciences, Inc. (NASDAQ:SAVA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,949 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned approximately 0.06% of Cassava Sciences as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Tidal Investments LLC bought a new stake in shares of Cassava Sciences in the third quarter worth $11,036,000. Geode Capital Management LLC boosted its stake in shares of Cassava Sciences by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,593 shares of the company’s stock worth $29,688,000 after buying an additional 41,289 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Cassava Sciences in the 3rd quarter valued at about $10,610,000. Wellington Management Group LLP acquired a new stake in shares of Cassava Sciences in the third quarter valued at about $605,000. Finally, Essex LLC raised its holdings in Cassava Sciences by 26.1% during the third quarter. Essex LLC now owns 69,774 shares of the company’s stock worth $2,053,000 after acquiring an additional 14,456 shares in the last quarter. Institutional investors own 38.05% of the company’s stock.

Cassava Sciences Trading Up 1.7 %

NASDAQ SAVA opened at $2.42 on Friday. The firm has a market capitalization of $116.43 million, a P/E ratio of -1.75 and a beta of -0.95. The firm’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $17.21. Cassava Sciences, Inc. has a 1 year low of $2.23 and a 1 year high of $42.20.

Analysts Set New Price Targets

Separately, HC Wainwright downgraded Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 price target for the company. in a research note on Tuesday, November 26th.

Insider Activity at Cassava Sciences

In other Cassava Sciences news, CFO Eric Schoen sold 59,800 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $3.86, for a total transaction of $230,828.00. Following the completion of the sale, the chief financial officer now owns 11,500 shares of the company’s stock, valued at $44,390. This trade represents a 83.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.00% of the stock is currently owned by company insiders.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.